JP5837079B2 - キナゾリン錯体、ならびにキナゾリン錯体の調製方法 - Google Patents

キナゾリン錯体、ならびにキナゾリン錯体の調製方法 Download PDF

Info

Publication number
JP5837079B2
JP5837079B2 JP2013535272A JP2013535272A JP5837079B2 JP 5837079 B2 JP5837079 B2 JP 5837079B2 JP 2013535272 A JP2013535272 A JP 2013535272A JP 2013535272 A JP2013535272 A JP 2013535272A JP 5837079 B2 JP5837079 B2 JP 5837079B2
Authority
JP
Japan
Prior art keywords
group
represented
general formula
imino
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013535272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542210A (ja
JP2013542210A5 (cg-RX-API-DMAC7.html
Inventor
福意 汪
福意 汪
群 羅
群 羅
麗云 紀
麗云 紀
偉 鄭
偉 鄭
爽 呂
爽 呂
鮮嬋 李
鮮嬋 李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Chemistry CAS
Original Assignee
Institute of Chemistry CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Chemistry CAS filed Critical Institute of Chemistry CAS
Publication of JP2013542210A publication Critical patent/JP2013542210A/ja
Publication of JP2013542210A5 publication Critical patent/JP2013542210A5/ja
Application granted granted Critical
Publication of JP5837079B2 publication Critical patent/JP5837079B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2013535272A 2010-10-27 2011-10-27 キナゾリン錯体、ならびにキナゾリン錯体の調製方法 Expired - Fee Related JP5837079B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010521382.4 2010-10-27
CN201010521382.4A CN102452988B (zh) 2010-10-27 2010-10-27 一种喹唑啉衍生物及其制备方法
PCT/CN2011/081453 WO2012055369A1 (zh) 2010-10-27 2011-10-27 一种抑制肿瘤细胞增殖的喹唑啉衍生物、喹唑啉配合物蛋白激酶抑制剂及它们的制备方法

Publications (3)

Publication Number Publication Date
JP2013542210A JP2013542210A (ja) 2013-11-21
JP2013542210A5 JP2013542210A5 (cg-RX-API-DMAC7.html) 2015-10-08
JP5837079B2 true JP5837079B2 (ja) 2015-12-24

Family

ID=45993179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013535272A Expired - Fee Related JP5837079B2 (ja) 2010-10-27 2011-10-27 キナゾリン錯体、ならびにキナゾリン錯体の調製方法

Country Status (5)

Country Link
US (1) US9233995B2 (cg-RX-API-DMAC7.html)
EP (1) EP2634178B1 (cg-RX-API-DMAC7.html)
JP (1) JP5837079B2 (cg-RX-API-DMAC7.html)
CN (1) CN102452988B (cg-RX-API-DMAC7.html)
WO (1) WO2012055369A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
WO2015142683A1 (en) * 2014-03-15 2015-09-24 Wake Forest University Functionalized tyrosine kinase inhibitors modified with precious metal electrophiles and methods associated therewith
EP2924045A1 (en) * 2014-03-25 2015-09-30 Medizinische Universität Wien New agents for the treatment of cancer
CN106188147B (zh) * 2015-05-08 2021-08-20 中国科学院化学研究所 含喹唑啉类配体的Pt配合物及其制备方法和应用
CN105153047A (zh) * 2015-08-25 2015-12-16 佛山市赛维斯医药科技有限公司 含新型苯并喹唑啉和邻位氟结构的酪氨酸激酶抑制剂及用途
CN105153046A (zh) * 2015-08-25 2015-12-16 佛山市赛维斯医药科技有限公司 双卤素取代的乙氧基苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN114524853B (zh) * 2022-02-28 2023-12-12 南京师范大学 一种全反式维甲酸-芳基金属配合物、制备方法及应用
CN116217550B (zh) * 2022-12-26 2024-12-27 上海前瞻创新研究院有限公司 一种咪唑三联吡啶钌配合物溶解氧检测探针及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527395A (ja) * 2000-03-17 2003-09-16 ノボ ノルディスク アクティーゼルスカブ ヒスタミンｈ３受容体リガンドとしての縮環イミダゾール
EA009300B1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
BRPI0414489A8 (pt) 2003-09-16 2019-01-15 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
GB0321620D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
WO2005097137A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
CN1313449C (zh) * 2005-07-14 2007-05-02 沈阳中海生物技术开发有限公司 新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
US20100234371A1 (en) * 2005-08-22 2010-09-16 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
US7977346B2 (en) * 2006-01-17 2011-07-12 Guoqing Paul Chen Spiro compounds and methods of use
SG174774A1 (en) * 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
US8119616B2 (en) * 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
JP5474792B2 (ja) * 2007-09-10 2014-04-16 キュリス，インコーポレイテッド 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体
CN101367793B (zh) * 2008-09-26 2013-09-11 中国科学院广州生物医药与健康研究院 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类

Also Published As

Publication number Publication date
US9233995B2 (en) 2016-01-12
EP2634178A4 (en) 2013-09-04
EP2634178A1 (en) 2013-09-04
US20130225811A1 (en) 2013-08-29
CN102452988B (zh) 2016-01-27
JP2013542210A (ja) 2013-11-21
WO2012055369A1 (zh) 2012-05-03
CN102452988A (zh) 2012-05-16
EP2634178B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
JP5837079B2 (ja) キナゾリン錯体、ならびにキナゾリン錯体の調製方法
Colina-Vegas et al. Half sandwich Ru (II)-acylthiourea complexes: DNA/HSA-binding, anti-migration and cell death in a human breast tumor cell line
CN101891627B (zh) 一种含有钌的配合物及其制备方法
Welsh et al. Synthesis and antiproliferative activity of benzimidazole-based, trinuclear neutral cyclometallated and cationic, N^ N-chelated ruthenium (ii) complexes
Elsayed et al. Synthesis, structural characterization and anticancer activity of some new complexes of 6-amino-4-hydroxy-2-thiopyrimidine
Patel et al. Dioxidovanadium (V) complexes of a tridentate ONO Schiff base ligand: Structural characterization, quantum chemical calculations and in-vitro antidiabetic activity
Talancon et al. Diastereomerically pure platinum (II) complexes as antitumoral agents.: The influence of the mode of binding {(N),(N, O)− or (C, N)}− of (1S, 2R)[(η5-C5H5) Fe {(η5-C5H4) CHNCH (Me) CH (OH) C6H5}] and the arrangement of the auxiliary ligands
CN114716436A (zh) Kras g12c突变抑制剂及其用途
Williams et al. Acridine-decorated cyclometallated gold (III) complexes: synthesis and anti-tumour investigations
WO2013178021A1 (zh) 吡咯并[2，1—f][1，2，4]三嗪衍生物及其抗肿瘤用途
Montanel-Pérez et al. The fluxional amine gold (III) complex as an excellent catalyst and precursor of biologically active acyclic carbenes
CN116143842A (zh) 氧化异阿朴菲生物碱与n-杂环卡宾的环金属铱配合物及其合成方法和应用
CN109369724A (zh) 一种有机砷化合物及其用途
El-Ghamry et al. Unexpected structure of enaminone Pd (II) complex in comparison with Cu (II) complex: Synthesis, characterization, DNA binding and antitumor activity
Karlık et al. Synthesis, structural characterization and cytotoxicity studies of T-shaped silver (I) complexes derived from 1-benzyl-3H-benzimidazolium p-toluenesulfonates
CN109053592B (zh) 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
Al-Rashdi et al. Dna-binding and antiproliferative properties of Palladium (II) complexes with tridentate ligands
CN110357795A (zh) 一种双胍衍生物、药物组合物、制备方法和其在制备抗肿瘤药物中的应用
Burgoyne et al. Synthesis and anticancer evaluation of mono-and trinuclear half-sandwich rhodium (III) and iridium (III) complexes based on N, O-salicylaldiminato-sulfonated scaffolds
Mojić et al. Synthesis, X-ray structure and strong in vitro cytotoxicity of novel organoruthenium complexes
CN109053594B (zh) 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
Mazur et al. N‐Allyl‐N‐ferrocenylmethylamines and ansa‐ferrocenylmethylamines: synthesis, structure, and biological evaluation
CN113336798B (zh) 一种基于三均嗪的三核铂配合物及其制备方法和应用
CN116023417A (zh) 氧化异阿朴菲生物碱的n-杂环卡宾型环金属钌配合物及其合成方法和应用
Wang et al. Cationic N, S-chelate half-sandwich iridium complexes: synthesis, characterization, anticancer and antiplasmodial activity

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141226

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20150129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150519

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151020

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151104

R150 Certificate of patent or registration of utility model

Ref document number: 5837079

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees